(Q43146799)

14 November 2017

title

Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer (English)

1 reference

14 November 2017

1 reference

Jordan Berlin

1

1 reference

14 November 2017

Al B Benson

series ordinal

2

1 reference

14 November 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Nature Reviews Clinical Oncology

14 November 2017

published in

1 reference

14 November 2017

volume

7

1 reference

14 November 2017

issue

3

1 reference

14 November 2017

page(s)

135-137

1 reference

14 November 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.16

10.1038/NRCLINONC.2010.16

31 March 2020

Identifiers

DOI

1 reference

14 November 2017

1 reference